Unlearn to Apply AI-Generated Digital Twins to the VectorY Therapeutics PIONEER-ALS Study

ALS is a fatal neurodegenerative disease with over 5,000 new U.S. diagnoses a year, more than 30,000 people currently living with it, and median survival of 2-3 years post-diagnosis; single-arm trials are often used in ALS drug development due to ethical concerns about placebo use in such a rapidly progressive, fatal condition. Unlearn partnered with VectorY Therapeutics to integrate AI-generated digital twins into VectorY's PIONEER-ALS Phase 1/2 study evaluating VTx-002, a first-in-class vectorized antibody targeting TDP-43 pathology, using Unlearn's ALS Digital Twin Generator (ALS-DTG) -- trained on historical ALS patient data -- to create individualized forecasts serving as patient-level external comparators. Unlearn CEO Steve Herne said the aim is to 'extract stronger evidence from every enrolled patient' for 'more confident development decisions in a disease where every data point matters'; VectorY's CMO said the approach will 'strengthen evidence generation from a single-arm design' while reducing patient burden and timelines.

Unlearn.AI builds AI-generated 'digital twins' of clinical-trial patients, formally qualified by the EMA and reviewed positively by the FDA for reducing control-arm size in real trials.

This sits in the Ship stage of the AI use-case lifecycle: Named examples from the vendors pharma teams use to get an AI system live inside a real, regulated production workflow — validation, CRM, safety and clinical systems of record.